Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 164, Issue 4, 1991, Pages 1038-1043

  Berek, Jonathan S ^a   Chung, Catherine ^a   Kaldi, Klara ^a   Watson, Joanna M ^a   Knox, Reba M ^a   Martínez Maza, Otoniel ^a  

^a NONE   (United States)

Author keywords

cytokines; Human ovarian cancer; interleukin 6; serum levels

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKINE; INTERLEUKIN 6; TUMOR MARKER;

ADULT; AGED; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL;

EID: 0025853795     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9378(91)90582-C     Document Type: Article

References (33)

1. Epithelial ovarian cancer
2. CA 125 for the monitoring of ovarian carcinoma during primary therapy
3. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2)
4. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines
5. Identification of the human 26-kD protein, interferon b2 (IFN-b2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor
6. B cell growth modulating and differentiating activity of recombinant human 26-kD protein (BSF-2, HuIFN-b2, HPGF)
7. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
8. Interferon b2/B cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte stimulating factor and regulates the major acute phase protein response in liver cells
9. B-cell-stimulating factor 2 (b2 interferon) functions as a second signal for interleukin 2 production by nature murine T cells
10. Human B cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production
11. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
12. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6
13. IFN-b2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines
14. B cell growth and differentiation induced by supernatants of transformed epithelial cell lines
15. Interleukin 6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas
16. Constitutive production of IL-6 by ovarian cancer cell lines and by primary ovarian tumor cultures
17. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis
18. Tumor invasion and metastasis
19. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer
20. Amplification of c-ras-Ki oncogene in human ovarian tumors
21. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products
22. Establishment of an interleukin 6 (IL-6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL-6 monoclonal antibodies
23. Infection with HIV is associated with elevated IL-6 levels and production
24. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas
25. Interleukin-6 immunoreactivity in human tumors
26. Characterization of a human ovarian teratocarcinoma-derived cell line
27. Interleukin-6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
28. Regulation of expression of interleukin-6: molecular and clinical studies
29. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
30. Multiple forms of IFN-b2/IL-6 in plasma and body fluids during acute phase bacterial infection
31. Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids
32. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast carcinoma cell lines
33. Biological and clinical aspects of interleukin 6